BIIB Q2 2025 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q2 2025 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.6B+7.3% YoY

Gross Profit

$1.7B64.2% margin

Operating Income

$588M22.2% margin

Net Income

$635M24.0% margin

EPS (Diluted)

$4.35

QoQ Revenue Growth

+8.8%

Cash Flow

Operating Cash Flow

$161M

Free Cash Flow

$144M

Stock-Based Comp.

$75M

Balance Sheet

Total Assets

$28.3B

Total Liabilities

$10.7B

Stockholders' Equity

$17.6B

Cash & Equivalents

$2.8B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.6B	$2.5B	+7.3%
Gross Profit	$1.7B	$1.5B	+12.6%
Operating Income	$588M	$367M	+60.5%
Net Income	$635M	$584M	+8.8%

Revenue Segments

MS Product Revenues

$1.1B42%

TYSABRI product

$455M17%

Fumarate

$406M16%

SPINRAZA

$393M15%

Interferon

$247M9%

Geographic Segments

UNITED STATES

$941M50%

Non-US

$938M50%